Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) – Cormark reduced their Q1 2017 earnings per share estimates for Cipher Pharmaceuticals in a research note issued on Monday. Cormark analyst D. Novak now expects that the firm will post earnings of $0.04 per share for the quarter, down from their prior estimate of $0.07. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.01 EPS.

Several other research firms also recently commented on CPH. GMP Securities downgraded shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th. TD Securities reaffirmed a “buy” rating and issued a C$7.50 price target on shares of Cipher Pharmaceuticals in a research note on Thursday, August 11th.

Earnings History and Estimates for Cipher Pharmaceuticals (TSE:CPH)

Cipher Pharmaceuticals (TSE:CPH) opened at 3.79 on Tuesday. The stock’s market capitalization is $99.28 million. Cipher Pharmaceuticals has a one year low of $3.50 and a one year high of $8.18. The firm has a 50-day moving average of $4.62 and a 200 day moving average of $6.06.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Receive News & Stock Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.